Corporate DispatchPro JENNIFER SABA VIA REUTERS BREAKINGVIEWS
Pfizer makes good on Covid M&A capacity Pfizer is taking its Covid-19 vaccine cash bounty and putting it to use. The U.S. drugmaker, valued at $273 billion at Friday’s market close, on Monday agreed to buy Trillium Therapeutics for $2.3 billion.
At $18.50 per share, the price represents a more than 200% premium to Trillium’s stock price. That may seem lofty, even by the biotechnology sector’s standards, but Pfizer had already bought a $25 million stake last year and Trillium’s stock was down nearly 60% so far in 2021. It’s also part of Pfizer’s broader strategy to develop its portfolio, even though the present is dominated by the coronavirus: The United States gave its full official approval to the vaccine co-developed with BioNTech to be marketed as Comirnaty read more. Trillium develops treatments for blood cancers like leukemia, which represent about 6% of all cancer cases worldwide last year. Even if the virus is more tenacious than expected, Pfizer has its eye on the future.
51
www.corporatedispatch.pro
